COXIBS: EVOLUTION OF A REVOLUTIONARY CLASS: EVOLVING CONCEPTS AND ISSUES SURROUNDING COX-2 INHIBITORS

Supplement 1 to Volume 69, April 2002

SUPPLEMENT EDITOR:
MARC C. HOCHBERG, MD, MPH
UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE

Preface 3

Development and clinical application of COX-2–selective inhibitors for the treatment of osteoarthritis and rheumatoid arthritis 5

Cyclooxygenase-2–selective inhibitors: Translating pharmacology into clinical utility 13

COX-2–selective inhibitors in the treatment of arthritis 20

Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2–selective inhibitors 31

Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors 40

Current perspective on the cardiovascular effects of coxibs 47

Renal effects of nonselective NSAIDS and coxibs 53

Developing an economic rationale for the use of selective COX-2 inhibitors for patients at risk for NSAID gastropathy 59

Cyclooxygenase-2–selective inhibitors in the management of acute and perioperative pain 65

Emerging options with coxib therapy 76

Copyright © 2002 by the Cleveland Clinic Educational Foundation.
The statements and opinions expressed in the Cleveland Clinic Journal of Medicine are those of the authors and not necessarily of The Cleveland Clinic Foundation or its Board of Trustees.

This supplement was supported by an educational grant from Merck & Co.

Author financial conflict-of-interest disclosures appear within the authors’ respective articles.